Alnylam Pharmaceuticals Advances Diabetes Drug Into Phase 2 Trial
Alnylam Pharmaceuticals (ALNY) has initiated a Phase 2 trial for its diabetes drug ALN-4324, aiming to improve insulin sensitivity. The trial is a triple-blind, placebo-controlled study, marking the company's expansion into the metabolic market. Truist lowered its price target for ALNY to $505 while maintaining a Buy rating.
Topics: Alnylam Pharmaceuticals clinical trials diabetes drug Phase 2 RNAi therapy